Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 1.74% | 306.72 | 0.0% | $5256.57m | |
| BNTX | BioNTech SE | 3.17% | 344.06 | 0.0% | $1596.83m | |
| NVAX | Novavax, Inc. | -0.92% | 160.48 | 78.2% | $831.00m | |
| AMGN | Amgen, Inc. | 0.63% | 202.44 | 1.4% | $596.39m | |
| GILD | Gilead Sciences, Inc. | -0.16% | 69.56 | 1.0% | $505.86m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.18% | 635.16 | 2.7% | $472.48m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.31% | 203.81 | 1.9% | $464.56m | |
| LGVN | Longeveron Inc. | 11.78% | 20.12 | 0.0% | $429.77m | |
| ILMN | Illumina, Inc. | -2.85% | 347.28 | 3.3% | $324.28m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -4.21% | 4.10 | 0.7% | $286.61m | |
| BIIB | Biogen, Inc. | -2.01% | 223.92 | 1.8% | $276.52m | |
| INCY | Incyte Corp. | -1.28% | 65.78 | 2.4% | $150.25m | |
| SGEN | Seagen Inc. | -5.00% | 150.74 | 5.8% | $149.09m | |
| EXAS | EXACT Sciences Corp. | -4.94% | 76.59 | 18.0% | $140.15m | |
| OCGN | Ocugen, Inc. | -8.72% | 5.76 | 0.0% | $139.18m |
Company Profile
Lumos Pharma, Inc. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Austin, TX.